Research programme: antivirals - Microbiotix

Drug Profile

Research programme: antivirals - Microbiotix

Alternative Names: MBX 468; MBX 685; MBX 769S

Latest Information Update: 27 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Microbiotix
  • Developer Microbiotix; University of Michigan
  • Class Antivirals; Cyclopropanes; Purine nucleosides; Small molecules
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C; Human herpesvirus 6 infections; Human herpesvirus 8 infections; Influenza A virus H5N1 subtype
  • Discontinued Epstein-Barr virus infections; Hepatitis B

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Human-herpesvirus-6-infections in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top